– Offers Clients an Integrated Portfolio for Biologic and Biosimilar
Drug Development –
WILMINGTON, Mass.--(BUSINESS WIRE)--Jun. 27, 2016--
Charles River Laboratories International, Inc. (NYSE: CRL) today
announced that it has acquired Blue Stream Laboratories, Inc. Combining
Blue Stream with Charles River’s existing discovery, safety assessment,
and biologics capabilities creates a leading provider with the ability
to support biologic and biosimilar development from characterization
through clinical testing and commercialization.
Blue Stream is an analytical contract research organization (CRO)
supporting the development of complex biologics and biosimilars. Located
in Woburn, Massachusetts, the company is recognized for its expertise in
structural and functional protein characterization programs, and the
development and validation of assays for current good manufacturing
practice (cGMP) lot release and stability programs. Protein
characterization is the key element for development and registration of
biologic and biosimilar entities.
James C. Foster, Chairman, President and Chief Executive Officer, said,
“Our continued investment in expanding our biologics portfolio, through
the development of new assays and capabilities, has enabled us to
provide a broader testing solution for our clients. This investment is
particularly important now, when the number of biologic and biosimilar
drugs in development is increasing. The acquisition of Blue Stream will
meaningfully enhance the ability of our Biologic Testing Solutions
business to compete effectively in this high-growth market segment.”
Caution Concerning Forward-Looking Statements
This news release includes forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements may be identified by the use of words such as “anticipate,”
“believe,” “expect,” “will,” “may,” “estimate,” “plan,” “outlook,” and
“project” and other similar expressions that predict or indicate future
events or trends or that are not statements of historical matters.
Forward-looking statements include statements in this press release
regarding the acquisition of Blue Stream Laboratories, Inc. (Blue
Stream) and Charles River’s expectations with respect to the impact of
Blue Stream on the Company and its product and service offerings;
Charles River’s projected future performance; as well as Charles River’s
future growth in the area of biologics and biosimilars. Forward-looking
statements are based on Charles River’s current expectations and
beliefs, and involve a number of risks and uncertainties that are
difficult to predict and that could cause actual results to differ
materially from those stated or implied by the forward-looking
statements. A further description of these risks, uncertainties, and
other matters can be found in the Risk Factors detailed in Charles
River's Annual Report on Form 10-K as filed on February 12, 2016, as
well as other filings we make with the Securities and Exchange
Commission. Because forward-looking statements involve risks and
uncertainties, actual results and events may differ materially from
results and events currently expected by Charles River, and Charles
River assumes no obligation and expressly disclaims any duty to update
information contained in this news release except as required by law.
About Charles River
Charles River provides essential products and services to help
pharmaceutical and biotechnology companies, government agencies and
leading academic institutions around the globe accelerate their research
and drug development efforts. Our dedicated employees are focused on
providing clients with exactly what they need to improve and expedite
the discovery, early-stage development and safe manufacture of new
therapies for the patients who need them. To learn more about our unique
portfolio and breadth of services, visit www.criver.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160627006324/en/
Source: Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc.
Investor Contact:
Susan
E. Hardy, 781-222-6190
Corporate Vice President, Investor Relations
susan.hardy@crl.com
or
Media
Contact:
Amy Cianciaruso, 781-222-6168
Corporate Vice
President, Public Relations
amy.cianciaruso@crl.com